洛米塔皮德:利用创新疗法应对心血管疾病的挑战
Undral Munkhsaikhan1, Karima Ait-Aissa1, Amal M Sahyoun1
1College of Dental Medicine, Lincoln Memorial University, LMU tower, 1705 St. Mary Street, Knoxville, TN, 37917, USA.
Molecular biology reports
|October 21, 2024
概括
脱脂症会增加心血管疾病的风险. 洛米塔皮德 (Lomitapide) 是一种微小的甘油三转移蛋白抑制剂,有效降低了对他类药物不反应的HoFH患者的LDL-C,从而降低了心血管风险.
科学领域:
- 心血管医学 心血管医学
- 药理学 药理学是指药理学的学科.
- 遗传学 是一个遗传学.
背景情况:
- 失脂症是心血管疾病 (CVD) 的首要危险因素.
- 同卵性家族高胆固醇血症 (HoFH) 是一种严重的遗传性疾病,其特征是极高的LDL-C水平.
- 类药物是失脂症的主要治疗方法,但HoFH患者往往表现出有限的反应.
研究的目的:
- 审查洛米塔皮德治疗治疗失脂症的治疗益处,特别是在HoFH.
- 为了突出罗米塔皮德在降低胆固醇水平和降低心血管疾病风险方面的有效性.
- 探索罗米塔皮德作为HoFH患者的替代疗法.
主要方法:
- 干预研究的系统审查和元分析.
- 专注于关于罗米塔皮德有效性的研究结果.
- 分析罗米塔皮德作为微小甘油转移蛋白 (MTP) 抑制剂的作用机制.
主要成果:
- 洛米塔皮德可显著降低LDL-C水平超过50%的HoFH患者.
- 洛米塔皮德降低了含有ApoB的蛋白质和VLDL,间接降低了LDL-C.
- 研究表明,用洛米塔皮德治疗可以改善血管功能,降低心血管风险.
结论:
- 洛米塔皮德是对其他治疗方法反应不足的HoFH患者的有效治疗选择.
- 用洛米塔皮德抑制MTP提供了一种新的方法来管理严重的脂质失调症.
- 使用洛米塔皮德降低LDL-C对于预防动脉样硬化和改善心血管健康至关重要.
相关概念视频
01:26Coronary Artery Disease IV: Medical Management
3
Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
3
01:29Cardiomyopathy V: Interprofessional Care
1
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
1
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
136
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
136
01:26Atherosclerosis III: Management
1
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
1
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
154
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
154
01:26Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers
142
Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
142